22177-92-0

Basic information

• Product Name: 4-(6-Chloropyrimidin-4-yl)morpholine
• Synonyms: 4-(6-chloro-4-pyrimidinyl)morpholine(SALTDATA: FREE);4-Chloro-6-(morpholin-4-yl)pyrimidine
• CAS NO: 22177-92-0
• Molecular Formula: C₈H₁₀ClN₃O
• Molecular Weight: 199.64
• Product Categories: Amines;blocks;alkyl chloride
• Mol File: 22177-92-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: 149-150℃
• Boiling Point: 366 °C at 760 mmHg
• Flash Point: 175.2 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 1.51E-05mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(6-Chloropyrimidin-4-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(6-Chloropyrimidin-4-yl)morpholine(22177-92-0)
• EPA Substance Registry System: 4-(6-Chloropyrimidin-4-yl)morpholine(22177-92-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 22177-92-0(Hazardous Substances Data)

Usage

Uses

4-(6-Chloropyrimidin-4-yl)morpholine

InChI:InChI=1/C8H10ClN3O/c9-7-5-8(11-6-10-7)12-1-3-13-4-2-12/h5-6H,1-4H2

Upstream product

• 110-91-8 morpholine 
• 1193-21-1 4,6-dichloropyrimidine 

Downstream Products

• 1375799-59-9 sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate 
• 5767-36-2 4-(6-hydrazinopyrimidin-4-yl)morpholine 
• 1312164-78-5 ethyl 4-(6-morpholinopyrimidin-4-yl)benzoate 

Relevant articles and documents

Pyrimidine derivatives as anti-diabetic agents

The pyrimidine derivatives as anti-diabetic agents are chloropyrimidinyl derivatives having the general formula of compound 81, wherein R1 is —N(CH3)CH2CH2OH (compound 81c) or —N(H)CH2CH2OH (compound 81f) or the general formula of compound 82, wherein R2 is —N(CH3)CH2CH2OH (compound 82c) or —N(CH2CH2)2O (compound 82d), as follows: The derivatives may be used for treating diabetes in humans or animals and have demonstrated efficacy, specifically in treating type 2 diabetes. Two methods of synthesizing the pyrimidine derivatives are described herein. The method using microwaves (Method B) is a green method that can provide high yields in a short time and with high purity. The compounds act as GLP-1 receptor agonists and are more potent than conventional drugs. As such, the compounds may be used in lower doses, and, hence, have fewer side effects.

O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS

Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.